Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

257
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
257
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

176
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
176
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Normal thromboelastography with a markedly prolonged activated partial thromboplastin time in severe prekallikrein deficiency: Implications for perioperative hemostatic assessment.

Transfusion·2026
Same author

A global survey of blood transfusion practices for patients with sickle cell disease.

Transfusion·2026
Same author

Alpha-Gal Syndrome: Unrecognized Risks of a Tick-Bite-Associated Allergy in Transplantation and Cellular Therapy.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

AABB survey on directed blood donation practices.

Transfusion·2026
Same author

Cost analysis considerations for red blood cell matching to mitigate alloimmunization in patients with sickle cell disease.

Transfusion·2026
Same author

A survey of transfusion support strategies for passenger lymphocyte syndrome in minor ABO-mismatched allogeneic hematopoietic stem cell transplantation.

Transfusion·2026

Related Experiment Video

Updated: Jan 7, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.2K

Factor XIII Supplementation in Postpartum Hemorrhage: From Biological Rationale to Clinical Implementation.

Jeremy W Jacobs1,2, Elizabeth A Abels3, Brian D Adkins4

  • 1Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee, USA.

American Journal of Hematology
|December 31, 2025
PubMed
Summary

Early Factor XIII supplementation may reduce maternal mortality from postpartum hemorrhage (PPH). This study investigates FXIII

More Related Videos

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.7K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.3K

Related Experiment Videos

Last Updated: Jan 7, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.2K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.7K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.3K

Area of Science:

  • Obstetrics and Gynecology
  • Hematology
  • Translational Medicine

Background:

  • Postpartum hemorrhage (PPH) is a leading cause of preventable maternal death.
  • Standard interventions and fibrinogen trials have shown limited success in reducing PPH-related mortality.
  • Coagulation Factor XIII (FXIII) activity decreases during pregnancy and PPH, suggesting a role in hemostasis.

Purpose of the Study:

  • To evaluate the efficacy of early FXIII supplementation in managing PPH.
  • To investigate FXIII as a potential therapeutic agent for PPH.
  • To address the unmet need for improved PPH interventions.

Main Methods:

  • The SWIFT trial (NCT06481995) is the first randomized controlled trial on early FXIII supplementation in PPH.
  • Observational studies indicate low antepartum FXIII predicts bleeding risk.
  • Ex vivo studies demonstrate FXIII supplementation restores clot firmness.

Main Results:

  • Observational data suggests low FXIII is linked to increased bleeding risk.
  • Ex vivo experiments show FXIII supplementation enhances clot stability.
  • The SWIFT trial is ongoing, evaluating early FXIII administration in PPH patients.

Conclusions:

  • FXIII plays a critical role in stabilizing blood clots.
  • Early FXIII supplementation is a promising strategy to improve PPH outcomes.
  • Addressing implementation challenges is crucial for the successful adoption of FXIII therapy in PPH management.